Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsRoland J. Fuchs, Ulrike Proetel, Katharina Kohlbrenner et al.|Leukemia|2017Cited by 339
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IVLida Kalmanti, Susanne Saußele, Michael Lauseker et al.|Leukemia|2015Cited by 274
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IVSusanne Saußele, Martin C. Müller, Marie-Paloma Krauß et al.|Blood|2015Cited by 200
Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligenceJan‐Niklas Eckardt, Jan Moritz Middeke, Waldemar Hahn et al.|npj Digital Medicine|2024Cited by 58
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestationsJan‐Niklas Eckardt, Jan Moritz Middeke, Friedrich Stölzel et al.|Journal of Hematology & Oncology|2022Cited by 58